Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00099294 · ClinicalTrials.gov registry record · Phase 3

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

A Phase 3 study, sponsored by Threshold Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target

NCT00099294: Completed Phase 3 study, sponsored by Threshold Pharmaceuticals.

NCT00099294 is a Phase 3 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00099294, a Phase 3 study, has completed, sponsored by Threshold Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target

Study Summary

The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with best supportive care.

Interventions

  • DRUG Glufosfamide

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2004-09
Est. Completion 2007-01
Phase Phase 3
Threshold Pharmaceuticals

9 total trials

What the finished NCT00099294 record still lists

NCT00099294 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 1 intervention - of which Glufosfamide is the first listed.

NCT00099294 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00099294 about?

NCT00099294 is a clinical study titled "Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer". The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with best supportive care.

What is the current status of trial NCT00099294?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-09. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00099294?

The interventions under investigation include: Glufosfamide (DRUG).

Who is sponsoring clinical trial NCT00099294?

This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00099294's enrollment target sits among peer trials

300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00099294, the US trial registry maintained by the National Library of Medicine. NCT00099294 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.